Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth J Pienta

Showing results (311-320 of 519) with videos related to

Pageof 52
Sort By:
Lab on a Chip|June 20, 2020
An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapesKe-Chih Lin, Yusha Sun, Gonzalo Torga, et al.
Clinical Genitourinary Cancer|October 19, 2016
Correlation of PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate CancerJeffrey J Tosoian, Michael A Gorin, Steven P Rowe, et al.
Cancer Research|May 17, 2008
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancerRohit Mehra, Scott A Tomlins, Jianjun Yu, et al.
The Prostate|November 27, 2024
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Marina Sharifi, Lisa N Chesner, et al.
Molecular Cancer Research : MCR|April 21, 2012
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancerAnjali Mishra, Jingcheng Wang, Yusuke Shiozawa, et al.
Neoplasia (New York, N.Y.)|September 13, 2013
TBK1 regulates prostate cancer dormancy through mTOR inhibitionJin Koo Kim, Younghun Jung, Jingcheng Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|November 8, 2008
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02Seth A Rosenthal, Kyoungwha Bae, Kenneth J Pienta, et al.
The Prostate|April 29, 2024
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Sophia C Kamran, Tamara Jamaspishvili, et al.
Cancer|January 28, 2003
Stromal factors involved in prostate carcinoma metastasis to boneCarlton R Cooper, Christopher H Chay, James D Gendernalik, et al.
International Journal of Oncology|May 5, 2005
Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biologyRobert D Loberg, Chris K Neeley, Lashon L Adam-Day, et al.
Pageof 52

Showing results (311-320 of 519) with videos related to

Sort By:
Pageof 52
Lab on a Chip|June 20, 2020
An in vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapesKe-Chih Lin, Yusha Sun, Gonzalo Torga, et al.
Clinical Genitourinary Cancer|October 19, 2016
Correlation of PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate CancerJeffrey J Tosoian, Michael A Gorin, Steven P Rowe, et al.
Cancer Research|May 17, 2008
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancerRohit Mehra, Scott A Tomlins, Jianjun Yu, et al.
The Prostate|November 27, 2024
Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Marina Sharifi, Lisa N Chesner, et al.
Molecular Cancer Research : MCR|April 21, 2012
Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancerAnjali Mishra, Jingcheng Wang, Yusuke Shiozawa, et al.
Neoplasia (New York, N.Y.)|September 13, 2013
TBK1 regulates prostate cancer dormancy through mTOR inhibitionJin Koo Kim, Younghun Jung, Jingcheng Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|November 8, 2008
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02Seth A Rosenthal, Kyoungwha Bae, Kenneth J Pienta, et al.
The Prostate|April 29, 2024
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy MeetingAndrea K Miyahira, Sophia C Kamran, Tamara Jamaspishvili, et al.
Cancer|January 28, 2003
Stromal factors involved in prostate carcinoma metastasis to boneCarlton R Cooper, Christopher H Chay, James D Gendernalik, et al.
International Journal of Oncology|May 5, 2005
Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biologyRobert D Loberg, Chris K Neeley, Lashon L Adam-Day, et al.
Pageof 52